These 2 Small-Cap Biotech And Pharma Stocks Boast “Strong Buy” Ratings And Significant Upside Potential
Today’s article highlights two “compelling small-cap stocks that combine a low cost of entry with the Street’s backing.” More specifically, these two stocks – a biotech firm and a pharmaceutical company – are currently trading for less than $8 a share, have earned “Strong Buy” consensus analyst ratings, and boast significant upside potential. For more, CLICK HERE.